The clinical management of hepatocellular carcinoma in China: Progress and challenges
Clinical and Molecular Hepatology · 01.04.2023 · 29 (2) · 339-341
DOI: 10.3350/cmh.2023.0077 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2023. Verfasst von Shan Shan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Liver Research Center, Beijing Friendship Hospital, Capital Medical University; The National Clinical Research Center for Digestive Diseases, Beijing…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
See the Original "Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective" on page 206.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Research Center, Beijing Friendship Hospital, Capital Medical University; The National Clinical Research Center for Digestive Diseases, Beijing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shan, S., & Jia, J. (2023). The clinical management of hepatocellular carcinoma in China: Progress and challenges. Clinical and Molecular Hepatology, 29(2), 339-341. https://doi.org/10.3350/cmh.2023.0077
Vancouver
Shan S, Jia J. The clinical management of hepatocellular carcinoma in China: Progress and challenges. Clinical and Molecular Hepatology. 2023;29(2):339-341. doi:10.3350/cmh.2023.0077
BibTeX
@article{Shan2023,
author = {Shan, Shan and Jia, Jidong},
title = {The clinical management of hepatocellular carcinoma in China: Progress and challenges},
journal = {Clinical and Molecular Hepatology},
year = {2023},
volume = {29},
number = {2},
pages = {339--341},
doi = {10.3350/cmh.2023.0077}
}
EUVIMED